PLA2G7 and coronary artery disorder: Other strategies have failed in coronary disease, including methotrexate, lipoprotein-associated phospholipase A2 inhibitors, p38 MAPK inhibitors, and complement blockades, likely reflecting off-target effects or unselected populations.